BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schuppan D, Hahn EG. Clinical studies with silymarin: fibrosis progression is the end point. Hepatology 2001;33:483-4. [PMID: 11172360 DOI: 10.1002/hep.510330230] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhao YZ, Qi ZP, Xu Q, Xiao XH, Guo F, Hou QY, Wei JC. Anti-hepatic fibrosis effect of total flavone from Litchi chinensis Sonn in rats with bile duct occlusion. Shijie Huaren Xiaohua Zazhi 2010; 18(20): 2084-2089 [DOI: 10.11569/wcjd.v18.i20.2084] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Herold C, Ganslmayer M, Deynet C, Hahn EG, Schuppan D. Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis: Prognostic factors for PBC. Liver 2002;22:159-65. [DOI: 10.1034/j.1600-0676.2002.01641.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
3 Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci 2008;53:1716-20. [PMID: 17940903 DOI: 10.1007/s10620-007-0052-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
4 Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis 2007;39:293-304. [PMID: 17331820 DOI: 10.1016/j.dld.2006.11.004] [Cited by in Crossref: 219] [Cited by in F6Publishing: 228] [Article Influence: 13.7] [Reference Citation Analysis]
5 Kanter M, Coskun O, Budancamanak M. Hepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats. World J Gastroenterol 2005; 11(42): 6684-6688 [PMID: 16425366 DOI: 10.3748/wjg.v11.i42.6684] [Cited by in CrossRef: 129] [Cited by in F6Publishing: 146] [Article Influence: 7.2] [Reference Citation Analysis]
6 Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 2005;12:559-67. [PMID: 16255756 DOI: 10.1111/j.1365-2893.2005.00636.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 6.4] [Reference Citation Analysis]
7 Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, Abdel-Hamid M, Shehata M, Abu-Baki L, Medhat A, Magder LS, Afdhal NH, Strickland GT. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis 2004;36:752-9. [PMID: 15571006 DOI: 10.1016/j.dld.2004.06.015] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 2.6] [Reference Citation Analysis]
8 Türkdoğan MK, Ozbek H, Yener Z, Tuncer I, Uygan I, Ceylan E. The role of Urtica dioica and Nigella sativa in the prevention of carbon tetrachloride-induced hepatotoxicity in rats. Phytother Res 2003;17:942-6. [PMID: 13680830 DOI: 10.1002/ptr.1266] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kanter M, Meral I, Dede S, Cemek M, Ozbek H, Uygan I, Gunduz H. Effects of Nigella sativa L. and Urtica dioica L. on Lipid Peroxidation, Antioxidant Enzyme Systems and Some Liver Enzymes in CCl4-Treated Rats. J Vet Med Series A 2003;50:264-8. [DOI: 10.1046/j.1439-0442.2003.00537.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 3.6] [Reference Citation Analysis]